A previous study in MS patients showed that IL-9 levels in the CSF were lower during clinical relapses and increased following prednisolone treatment, thus supporting the role of IL-9 in the maintenance of the remission phase in MS [148]. This evidence concerns the gene IL9 and myeloid sarcoma.